MedTrace Logo

Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer

NCT04126525 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2025-09-11

No results posted yet for this study

Summary

This is a prospective, open label study to evaluate the efficacy and safety of neoadjuvant pyrotinib in early breast cancer patients.

Conditions

  • Breast Cancer Female

Interventions

DRUG

Pyrotinib

dual HER2 blockade in the neoadjuvant setting

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Jinsong Lu · RenJi Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-18
Primary Completion
2021-10-28
Completion
2026-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04126525 on ClinicalTrials.gov